These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22855730)

  • 21. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
    Gromada J; Ding WG; Barg S; Renström E; Rorsman P
    Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
    Chan SW; Lin G; Yew DT; Rudd JA
    Eur J Pharmacol; 2011 Oct; 668(1-2):340-6. PubMed ID: 21756894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
    Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
    Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells.
    Moens K; Berger V; Ahn JM; Van Schravendijk C; Hruby VJ; Pipeleers D; Schuit F
    Diabetes; 2002 Mar; 51(3):669-75. PubMed ID: 11872665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations.
    Pinney SE; MacMullen C; Becker S; Lin YW; Hanna C; Thornton P; Ganguly A; Shyng SL; Stanley CA
    J Clin Invest; 2008 Aug; 118(8):2877-86. PubMed ID: 18596924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exendin(9-39)NH
    Gasbjerg LS; Bari EJ; Christensen M; Knop FK
    Diabetes Obes Metab; 2021 Nov; 23(11):2419-2436. PubMed ID: 34351033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by K(ATP) channel mutations.
    Fourtner SH; Stanley CA; Kelly A
    J Pediatr; 2006 Jul; 149(1):47-52. PubMed ID: 16860127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
    Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
    J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.
    Holz GG
    Horm Metab Res; 2004; 36(11-12):787-94. PubMed ID: 15655710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
    Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
    Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M; Ahrén B
    Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism.
    MacDonald PE; Salapatek AM; Wheeler MB
    Diabetes; 2002 Dec; 51 Suppl 3():S443-7. PubMed ID: 12475788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.
    García-Flores M; Zueco JA; Alvarez E; Blázquez E
    Eur J Biochem; 2001 Feb; 268(3):514-20. PubMed ID: 11168389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.